Blood Plasma Derivatives Market by Type, Application, and Other Application), and End User - Global Opportunity Analysis and Industry Forecast, 2016-2023

  • ID: 4580569
  • Report
  • Region: Global
  • 240 pages
  • Allied Analytics LLP
1 of 4
Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

The global blood plasma derivatives market was valued at $23,613 million in 2016, and is projected to reach $44,333 million at a CAGR of 9.3% from 2017 to 2023. The major factor that contributes towards the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors boosting the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The global blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other application. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed for North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global blood plasma derivatives market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments

By Type

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

By Application

Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
von Willebrand's disease (vWD)
Other Application

By End User

Hospitals
Clinics
Other End Users

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Grifols, S.A.
SK Plasma Co., Ltd.
Fusion Health Care Pvt. Ltd.
Biotest AG
Green Cross Corporation
Baxter International Inc.
LFB S.A.
Octapharma AG
CSL Limited
Shire Plc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. By Type
1.3.2. By Application
1.3.3. By End User
1.3.4. By Region
1.3.5. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. High prevalence of life threatening diseases
3.4.1.2. Growth in awareness about blood and plasma donation
3.4.1.3. Rise in geriatric population
3.4.1.4. High adoption of blood plasma derivatives
3.4.2. Restraints
3.4.2.1. High cost of blood plasma derivatives based therapy
3.4.2.2. Risks associated with plasma derivatives
3.4.3. Opportunities
3.4.3.1. Development of better methods for plasma derivatives manufacturing
3.4.3.2. Opportunities in emerging economies
3.4.4. Impact analyses
3.5. Government regulations
3.5.1. Plasma derivatives regulations in United States and Europe

CHAPTER 4: BLOOD PLASMA DERIVATIVES MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Albumin
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Factor VIII
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Factor IX
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Immunoglobulin
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Hyperimmune globulin
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast (value)
5.2. Hemophilia
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Hypogammaglobulinemia
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Immunodeficiency diseases
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. von Willebrand's disease (vWD)
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Other application
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

CHAPTER 6: BLOOD PLASMA DERIVATIVES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Clinics
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Other end users
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: BLOOD PLASMA DERIVATIVES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America blood plasma derivatives market, by country
7.2.2.1. U.S.
7.2.2.1.1. Market size and forecast, by type
7.2.2.1.2. Market size and forecast, by application
7.2.2.1.3. Market size and forecast, by end user
7.2.2.2. Canada
7.2.2.2.1. Market size and forecast, by type
7.2.2.2.2. Market size and forecast, by application
7.2.2.2.3. Market size and forecast, by end user
7.2.2.3. Mexico
7.2.2.3.1. Market size and forecast, by type
7.2.2.3.2. Market size and forecast, by application
7.2.2.3.3. Market size and forecast, by end user
7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Market size and forecast, by type
7.3.2.1.2. Market size and forecast, by application
7.3.2.1.3. Market size and forecast, by end user
7.3.2.2. France
7.3.2.2.1. Market size and forecast, by type
7.3.2.2.2. Market size and forecast, by application
7.3.2.2.3. Market size and forecast, by end user
7.3.2.3. UK
7.3.2.3.1. Market size and forecast, by type
7.3.2.3.2. Market size and forecast, by application
7.3.2.3.3. Market size and forecast, by end user
7.3.2.4. Italy
7.3.2.4.1. Market size and forecast, by type
7.3.2.4.2. Market size and forecast, by application
7.3.2.4.3. Market size and forecast, by end user
7.3.2.5. Spain
7.3.2.5.1. Market size and forecast, by type
7.3.2.5.2. Market size and forecast, by application
7.3.2.5.3. Market size and forecast, by end user
7.3.2.6. Rest of Europe
7.3.2.6.1. Market size and forecast, by type
7.3.2.6.2. Market size and forecast, by application
7.3.2.6.3. Market size and forecast, by end user
7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Market size and forecast, by type
7.4.2.1.2. Market size and forecast, by application
7.4.2.1.3. Market size and forecast, by end user
7.4.2.2. China
7.4.2.2.1. Market size and forecast, by type
7.4.2.2.2. Market size and forecast, by application
7.4.2.2.3. Market size and forecast, by end user
7.4.2.3. India
7.4.2.3.1. Market size and forecast, by type
7.4.2.3.2. Market size and forecast, by application
7.4.2.3.3. Market size and forecast, by end user
7.4.2.4. Australia
7.4.2.4.1. Market size and forecast, by type
7.4.2.4.2. Market size and forecast, by application
7.4.2.4.3. Market size and forecast, by end user
7.4.2.5. South Korea
7.4.2.5.1. Market size and forecast, by type
7.4.2.5.2. Market size and forecast, by application
7.4.2.5.3. Market size and forecast, by end user
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Market size and forecast, by type
7.4.2.6.2. Market size and forecast, by application
7.4.2.6.3. Market size and forecast, by end user
7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Market size and forecast, by type
7.5.2.1.2. Market size and forecast, by application
7.5.2.1.3. Market size and forecast, by end user
7.5.2.2. Saudi Arabia
7.5.2.2.1. Market size and forecast, by type
7.5.2.2.2. Market size and forecast, by application
7.5.2.2.3. Market size and forecast, by end user
7.5.2.3. South Africa
7.5.2.3.1. Market size and forecast, by type
7.5.2.3.2. Market size and forecast, by application
7.5.2.3.3. Market size and forecast, by end user
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Market size and forecast, by type
7.5.2.4.2. Market size and forecast, by application
7.5.2.4.3. Market size and forecast, by end user
7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Biotest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Fusion Health Care Pvt. Ltd.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.5. Grifols S.A.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Green Cross Holdings Corporation (Green Cross Corp.)
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. LFB SA (LFB Biotechnologies SAS)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Octapharma AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Shire Plc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. SK chemicals (SK Plasma Co., Ltd.)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Blood Plasma Derivatives Market, by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023" the global blood plasma derivatives market was valued at $23,613 million in 2016, and is projected to reach $44,333 million in 2023, registering a CAGR of 9.3% from 2017 to 2023.

Blood plasma is clear liquid component of blood in which red blood cells, white blood cells, and platelets are suspended. It plays a vital role in maintaining proper pH balance in the body and transporting nutrients throughout the body. It is composed of more than 100 different proteins, including albumin, fibrinogen, immunoglobulins, protease inhibitors, and clotting factors. Plasma derivatives are products that are derived from blood plasma on fractionation, and are widely used to treat variety of diseases. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III concentrate.

The factors that drive the growth of the blood plasma derivatives market include increase in prevalence of life-threatening diseases such as immunodeficiency diseases and hemophilia, rise in awareness towards blood & plasma donation, upsurge in geriatric population, and growth in adoption of blood plasma derivatives products. However, high cost of plasma derivative-based treatment and risk of side effects associated after using plasma derivatives impede the market growth. Conversely, the development of superior methods for preservation of plasma derivatives along with advanced processes for fractionation and presence of untapped market in emerging economies are expected to provide lucrative growth opportunities for the market.

The immunoglobulin segment accounted for the largest share in 2016, owing to high usage & applicability for treating variety of immunodeficiency diseases and improved immunoglobulin production due to the emergence of advanced technologies. However, the albumin segment is expected to grow at the high CAGR from 2017 to 2023.

The utilization rate of plasma derivatives for immunodeficiency diseases is high. However, hemophilia segment is expected to grow at a high CAGR during the forecast period. On the basis of end user, the hospitals segment occupied the largest share in 2016, whereas the clinics segment is expected to provide lucrative market opportunities during the forecast period.

Key findings of the Blood Plasma Derivatives Market:

The albumin segment accounted for nearly one-sixth share of the global blood plasma derivatives market in 2016.
The immunoglobulins segment is expected to grow at highest CAGR from 2017 to 2023.
The immunodeficiency diseases segment accounted for around one-third share of the global market in 2016.
Europe accounted for around one-third share of the global market in 2016.
LAMEA is expected to provide lucrative market growth opportunities from 2017 to 2023.

North America was the leading revenue contributor to the global blood plasma derivatives market in 2016, and is expected to dominate the market during the forecast period. This is attributed to the early approval of plasma derivatives products and large number of fractionation plants in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness towards plasma derivatives.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll